Leerink Partnrs Predicts Lower Earnings for PTC Therapeutics

Key Points

• Leerink Partners has revised its FY2025 earnings per share estimate for PTC Therapeutics from $8.61 to $8.24, amid a backdrop of decreased earnings expectations.
• Despite this revision, the current consensus estimate remains significantly lower at ($4.52) per share.
• Several analysts have varied opinions on PTC Therapeutics, with ratings ranging from "strong buy" to "sell," and a consensus price target set at $69.85.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities research analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of PTC Therapeutics in a research note issued to investors on Thursday, August 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings of $8.24 per share for the year, down from their previous forecast of $8.61. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

A number of other brokerages have also recently weighed in on PTCT. Cowen reaffirmed a "hold" rating on shares of PTC Therapeutics in a research report on Friday, August 8th. Cantor Fitzgerald boosted their price target on PTC Therapeutics from $112.00 to $120.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 29th. JPMorgan Chase & Co. reduced their price target on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Bank of America boosted their price objective on PTC Therapeutics from $68.00 to $84.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Finally, Wall Street Zen cut PTC Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $70.15.

PTC Therapeutics Stock Down 0.2%

Shares of NASDAQ:PTCT traded down $0.10 on Monday, reaching $48.07. The company had a trading volume of 300,375 shares, compared to its average volume of 1,062,850. PTC Therapeutics has a twelve month low of $30.41 and a twelve month high of $58.38. The stock has a 50-day moving average price of $49.16 and a 200 day moving average price of $48.92. The stock has a market capitalization of $3.82 billion, a P/E ratio of 6.89 and a beta of 0.54.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.24. The firm had revenue of $178.88 million during the quarter, compared to analysts' expectations of $173.01 million. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%. The business's revenue for the quarter was down 4.2% on a year-over-year basis. During the same quarter last year, the firm earned ($1.29) earnings per share.

Insider Activity

In other news, CEO Matthew B. Klein sold 10,739 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $51.74, for a total value of $555,635.86. Following the sale, the chief executive officer directly owned 337,767 shares in the company, valued at approximately $17,476,064.58. This represents a 3.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Mark Elliott Boulding sold 883 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $46.02, for a total value of $40,635.66. Following the sale, the vice president owned 103,901 shares in the company, valued at approximately $4,781,524.02. This trade represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,138 shares of company stock worth $720,713. Company insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC acquired a new position in PTC Therapeutics during the 1st quarter worth $595,000. Allspring Global Investments Holdings LLC acquired a new position in PTC Therapeutics during the 1st quarter worth $524,000. Cerity Partners LLC acquired a new position in PTC Therapeutics during the 1st quarter worth $641,000. Edgestream Partners L.P. acquired a new position in PTC Therapeutics during the 1st quarter worth $418,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in PTC Therapeutics by 49.2% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 46,894 shares of the biopharmaceutical company's stock worth $2,117,000 after buying an additional 15,459 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.